Precision BioSciences Q4 net income $20.1M, PBGENE-HBV shows antiviral activity, cash runway through 2028

PRECISION BIOSCIENCES INC

Q4 net income $20.1M ($1.05 diluted EPS) vs net loss $17.8M YoY; FY net loss $45.7M ($3.56/sh).
Cash, equivalents, restricted cash $137.2M as of Dec 31, 2025; $75M Nov 2025 financing extends runway through 2028.
PBGENE-HBV Phase 1: 13 patients dosed across 5 cohorts; late-breaking data showed safety, dose-dependent antiviral activity and HBsAg declines.
PBGENE-DMD received IND clearance Feb 2026; Fast Track & Orphan Drug designations; initial data from multiple patients expected year-end 2026.
Milestone payments: $8M from Imugene (Oct 2025) and $7.5M from TG Therapeutics (Mar 2026).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.